Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.

Pfizer moves to take PF-07934040 into its first clinical trial.

The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.

Supply continues to cause headaches for radiopharmaceutical developers.

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.

The group is keeping faith with the novel target KLK2.

Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.

Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.

Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.